Join us at the Truist Securities Oncology/Cell Tx Innovation: The Texas Trifecta, including MD Anderson, Baylor (BCM) & Rice University. Engage with top resident experts on ADCs, IO and Cell Therapy, and more. Learn more at bit.ly/3UUD34l
Truist Securities’ Post
More Relevant Posts
-
Wedbush Equity Research Analyst, Andreas Argyrides Launches Coverage on Sarepta Therapeutics (SRPT). Andreas Argyrides initiates coverage on Sarepta Therapeutics (SRPT) with a 12-month price target of $224. Sarepta is a biotech leader specializing in therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). 🧬 In its first quarter, ELEVIDYS exceeded sales expectations, showcasing Sarepta's swift execution and robust market demand. Projected FY30 sales stand at an impressive $8.7BN, with a U.S. penetration of 46.0%. Sarepta's dominance in DMD poses a significant hurdle to gene therapy competitors. Notably, Sarepta's 12-month price target is set at $224, signaling a promising future for investors.
Wedbush Initiates Coverage on SRPT
https://www.wedbush.com
To view or add a comment, sign in
-
Wedbush Equity Research Analyst, Andreas Argyrides Launches Coverage on Sarepta Therapeutics (SRPT). Andreas Argyrides initiates coverage on Sarepta Therapeutics (SRPT) with a 12-month price target of $224. Sarepta is a biotech leader specializing in therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). 🧬 In its first quarter, ELEVIDYS exceeded sales expectations, showcasing Sarepta's swift execution and robust market demand. Projected FY30 sales stand at an impressive $8.7BN, with a U.S. penetration of 46.0%. Sarepta's dominance in DMD poses a significant hurdle to gene therapy competitors. Notably, Sarepta's 12-month price target is set at $224, signaling a promising future for investors.
Wedbush Initiates Coverage on SRPT
https://www.wedbush.com
To view or add a comment, sign in
-
Wedbush Equity Research Analyst, Andreas Argyrides Launches Coverage on Sarepta Therapeutics (SRPT). Andreas Argyrides initiates coverage on Sarepta Therapeutics (SRPT) with a 12-month price target of $224. Sarepta is a biotech leader specializing in therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). 🧬 In its first quarter, ELEVIDYS exceeded sales expectations, showcasing Sarepta's swift execution and robust market demand. Projected FY30 sales stand at an impressive $8.7BN, with a U.S. penetration of 46.0%. Sarepta's dominance in DMD poses a significant hurdle to gene therapy competitors. Notably, Sarepta's 12-month price target is set at $224, signaling a promising future for investors.
Wedbush Initiates Coverage on SRPT
https://www.wedbush.com
To view or add a comment, sign in
-
Wedbush Equity Research Analyst, Andreas Argyrides Launches Coverage on Sarepta Therapeutics (SRPT). Andreas Argyrides initiates coverage on Sarepta Therapeutics (SRPT) with a 12-month price target of $224. Sarepta is a biotech leader specializing in therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). 🧬 In its first quarter, ELEVIDYS exceeded sales expectations, showcasing Sarepta's swift execution and robust market demand. Projected FY30 sales stand at an impressive $8.7BN, with a U.S. penetration of 46.0%. Sarepta's dominance in DMD poses a significant hurdle to gene therapy competitors. Notably, Sarepta's 12-month price target is set at $224, signaling a promising future for investors.
Wedbush Initiates Coverage on SRPT
https://www.wedbush.com
To view or add a comment, sign in
-
Wedbush Equity Research Analyst, Andreas Argyrides Launches Coverage on Sarepta Therapeutics (SRPT). Andreas Argyrides initiates coverage on Sarepta Therapeutics (SRPT) with a 12-month price target of $224. Sarepta is a biotech leader specializing in therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). 🧬 In its first quarter, ELEVIDYS exceeded sales expectations, showcasing Sarepta's swift execution and robust market demand. Projected FY30 sales stand at an impressive $8.7BN, with a U.S. penetration of 46.0%. Sarepta's dominance in DMD poses a significant hurdle to gene therapy competitors. Notably, Sarepta's 12-month price target is set at $224, signaling a promising future for investors.
Wedbush Initiates Coverage on SRPT
https://www.wedbush.com
To view or add a comment, sign in
-
$AONCW - Fall after changed: dtocw?: Debt can assist American Oncology until it has trouble settling it off, either with new capital or with free cash flow. So, American Oncology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like American Oncology Network sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for American to invest in growth at high rates of return. When we think about American Oncology's use of debt, we should always consider it together with cash and equity. https://lnkd.in/gwv8GKC5 #stocks #stocktwits #thematic_portfolio
To view or add a comment, sign in
-
Medical communications | Scientific storyteller | Clinical trials | Oncology | Neurology | Women's health | Omaha | Blood donor
Are you or a loved one at increased risk of breast cancer and live in Nebraska? If so, please reach out to members of our legislature to ask them to support bill LB1353. Those at greater risk of breast cancer due to a family history of cancer, genetic mutation, or other factors that increase risk would benefit from this bill by providing breast cancer screening and diagnostic imaging with no cost-sharing for the patient, ensuring these crucial services are accessible to individuals at hight risk of cancer. FORCE: Facing Our Risk of Cancer Empowered is partnering with Susan G. Komen to support this bill because individuals at risk of hereditary cancer often need to start screening at a younger age, when they are less financially stable, and require more frequent screenings than those at average-risk. Often, these patients may forgo guideline-recommended screening because of the cost. However, individuals with knowledge of their predisposition to hereditary breast cancer have the greatest potential for preventing cancer and detecting it early when it is easier and less expensive to treat, so screening services need to be accessible to this community. Please join me in contacting our representatives and encouraging them to support this important bill. #BreastCancer #HereditaryCancer #1FORCECommunity #Nebraska https://lnkd.in/gbtbPggG
Banking, Commerce and Insurance Committee
nebraskalegislature.gov
To view or add a comment, sign in
-
Learn more about the innovative "#PulsePrime" approach with Roger Waltzman, Chief Medical Officer at Indaptus Therapeutics (NASDAQ: INDP), as he explains how the novel therapy, Decoy20, is set to revolutionize #cancertreatment. This method involves administering a rapid, potent dose of engineered bacteria directly into the bloodstream—unlike traditional therapies, this "pulse" is brief yet effective enough to activate and prime the #immunesystem without the prolonged exposure that can lead to side effects. This intermittent dosing strategy aims to enhance the immune system's responsiveness and reduce potential adverse reactions, offering new hope to more patients battling advanced cancer. Watch to learn more about how they're harnessing the body's defenses to fight cancer more effectively. https://lnkd.in/gFAVuwMi #IndaptusTherapeutics #CancerResearch #Decoy20 #biotech #ImmunoOncology
What is the “Pulse Prime” approach?
https://www.youtube.com/
To view or add a comment, sign in